Clinical trial
Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed…
NCT00350727 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00350727 |
|---|---|
| Title | Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma |
| Official title | Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma |
| Acronym | VEG102857 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma |
| Intervention type | Drug |
| Interventions | pazopanib, lapatinib |
| Enrollment | 75 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jul 11, 2006 |
| Last update posted | Apr 19, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: